SG11201809004PA - (+)-azasetron for use in the treatment of ear disorders - Google Patents
(+)-azasetron for use in the treatment of ear disordersInfo
- Publication number
- SG11201809004PA SG11201809004PA SG11201809004PA SG11201809004PA SG11201809004PA SG 11201809004P A SG11201809004P A SG 11201809004PA SG 11201809004P A SG11201809004P A SG 11201809004PA SG 11201809004P A SG11201809004P A SG 11201809004PA SG 11201809004P A SG11201809004P A SG 11201809004PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- azasetron
- ear disorders
- rue
- Prior art date
Links
- 229950005951 azasetron Drugs 0.000 title abstract 3
- 208000032625 disorder of ear Diseases 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 October 2017 (19.10.2017) WIPO I PCT (10) International Publication Number WO 2017/178645 Al 1111111111111101110111111111110101111101110101111101111111111111111111111110111111 (51) International Patent Classification: A61K 31/538 (2006.01) A61P 27/16 (2006.01) (21) International Application Number: PCT/EP2017/059058 (22) International Filing Date: 14 April 2017 (14.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/322,690 14 April 2016 (14.04.2016) US 16180192.3 19 July 2016 (19.07.2016) EP (71) Applicant: SENSORION [FR/FR]; 375 rue du Professeur Joseph Blayac, 34080 Montpellier (FR). (72) Inventor: DYHRFJELD-JOHNSEN, Jonas; 28 rue du Dardalhon, 34400 Lunel-Viel (FR). (74) Agent: ICOSA; 83 avenue Denfert-Rochereau, 75014 Par- is (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) W O 20 1717 / 86 45 Al (54) Title: (+)-AZASETRON FOR USE IN THE TREATMENT OF EAR DISORDERS (57) : The present invention relates to (+)-azasetron, or a pharmaceutically acceptable salt and/or solvate thereof, for treat - ing ear disorders.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322690P | 2016-04-14 | 2016-04-14 | |
| EP16180192 | 2016-07-19 | ||
| PCT/EP2017/059058 WO2017178645A1 (en) | 2016-04-14 | 2017-04-14 | (+)-azasetron for use in the treatment of ear disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809004PA true SG11201809004PA (en) | 2018-11-29 |
Family
ID=60042388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809004PA SG11201809004PA (en) | 2016-04-14 | 2017-04-14 | (+)-azasetron for use in the treatment of ear disorders |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3442537B1 (en) |
| KR (1) | KR102429935B1 (en) |
| AU (1) | AU2017248618B2 (en) |
| BR (1) | BR112018071123A2 (en) |
| CA (1) | CA3020847A1 (en) |
| EA (1) | EA038516B1 (en) |
| MA (1) | MA44660B1 (en) |
| SG (1) | SG11201809004PA (en) |
| WO (1) | WO2017178645A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220265668A1 (en) | 2019-07-25 | 2022-08-25 | Sensorion | Treatment and/or prevention of lesions in the central auditory nervous system |
| TW202400180A (en) * | 2022-03-16 | 2024-01-01 | 法商聖索瑞恩公司 | Azasetron for the treatment of sudden sensorineural hearing loss |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1304082C (en) | 1987-10-22 | 1992-06-23 | Tetsuya Tahara | Benzoxazine compounds and pharmaceutical use thereof |
| GB0104554D0 (en) * | 2001-02-23 | 2001-04-11 | Glaxo Group Ltd | New uses |
| AU2003216379A1 (en) * | 2002-02-22 | 2003-09-09 | Control Delivery Systems, Inc. | Method for treating otic disorders |
| PT2432467T (en) * | 2009-05-20 | 2018-04-04 | Inst Nat Sante Rech Med | Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders |
| ES2432618T3 (en) * | 2009-05-20 | 2013-12-04 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of a pathology of the inner ear with vestibular deficit |
| CN101786963B (en) | 2010-03-03 | 2013-05-08 | 山东众诚药业股份有限公司 | Synthesis method of Azasetron intermediate |
| CN104557906A (en) | 2015-01-21 | 2015-04-29 | 扬子江药业集团四川海蓉药业有限公司 | Method for preparing azasetron hydrochloride |
| PL3297628T3 (en) * | 2015-05-18 | 2021-12-06 | Sensorion | Azasetron for use in the treatment of hearing loss |
-
2017
- 2017-04-14 AU AU2017248618A patent/AU2017248618B2/en active Active
- 2017-04-14 CA CA3020847A patent/CA3020847A1/en active Pending
- 2017-04-14 EP EP17717441.4A patent/EP3442537B1/en active Active
- 2017-04-14 BR BR112018071123A patent/BR112018071123A2/en active Search and Examination
- 2017-04-14 WO PCT/EP2017/059058 patent/WO2017178645A1/en active Application Filing
- 2017-04-14 SG SG11201809004PA patent/SG11201809004PA/en unknown
- 2017-04-14 MA MA44660A patent/MA44660B1/en unknown
- 2017-04-14 EA EA201800565A patent/EA038516B1/en unknown
- 2017-04-14 KR KR1020187032487A patent/KR102429935B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017248618A1 (en) | 2018-11-08 |
| KR20180129923A (en) | 2018-12-05 |
| MA44660B1 (en) | 2024-03-29 |
| BR112018071123A2 (en) | 2019-02-05 |
| WO2017178645A1 (en) | 2017-10-19 |
| KR102429935B1 (en) | 2022-08-08 |
| AU2017248618B2 (en) | 2023-02-09 |
| EP3442537A1 (en) | 2019-02-20 |
| EP3442537B1 (en) | 2024-01-10 |
| EA038516B1 (en) | 2021-09-09 |
| CA3020847A1 (en) | 2017-10-19 |
| EA201800565A1 (en) | 2019-03-29 |
| MA44660A (en) | 2019-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
| SG11201907217RA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor |